Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer

被引：0

作者：

Gupta, Shilpa

Munster, Pamela N.

Hollebecque, Antoine

Argues, Guillem

Dajanl, Olav

Chang, Jonathan D.

Swift, Ann M.

Tosolini, Alessandra

Piha-Paul, Sarina Anne

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[2] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[6] Merck & Co Inc, Whitehouse Stn, NJ USA

[7] Merck & Co Inc, N Wales, PA USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.2509

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2509

引用

页数：1

共 49 条

[31] Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698)
Lara, Primo
Longmate, Jeff
Mack, Philip C.
Kelly, Karen
Socinski, Mark A.
Salgia, Ravi
Gitlitz, Barbara Jennifer
Li, Tianhong
Koczywas, Marianna
Reckamp, Karen L.
Gandara, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[32] Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Wolf, Denise
Yau, Christina
Brown-Swigart, Lamorna
Hirst, Gillian
Schmidt, Emmett
Townson, Steven
Cristescu, Razvan
Asare, Smita
Berry, Don
Esserman, Laura
van't Veer, Laura
Tripathy, Debu
Chien, Jo
CANCER RESEARCH, 2018, 78 (04)
[33] Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
Ramanathan, Ramesh K.
McDonough, Shannon L.
Kennecke, Hagen F.
Iqbal, Syma
Baranda, Joaquina C.
Seery, Tara E.
Lim, Howard J.
Hezel, Aram F.
Vaccaro, Gina M.
Blanke, Charles D.
CANCER, 2015, 121 (13) : 2193 - 2197
[34] A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group trial (S1005).
Ramanathan, Ramesh K.
McDonough, Shannon L.
Kennecke, Hagen F.
Iqbal, Syma
Baranda, Joaquina Celebre
Seery, Tara Elisabeth
Lim, Howard John
Hezel, Aram F.
Vaccaro, Gina M.
Blanke, Charles David
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[35] Computational drug repositioning identifies Akt inhibitor MK2206 binding to EZH2 as enhancer of Tazmetostat efficacy in inhibition of triple negative breast cancer proliferation
Thirumugam, Gowripriya
Sarathy, Gautham
Verma, Shiv
Dhekne, Shivani
Krishnaswamy, Balamurugan
Gupta, Sanjay
Ramaswamy, Bhuvaneswari
Shankar, Eswar
CANCER RESEARCH, 2023, 83 (07)
[36] Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
B. B. Y. Ma
B. C. Goh
W. T. Lim
E. P. Hui
E. H. Tan
G. de Lima Lopes
K. W. Lo
L. Li
H. Loong
N. R. Foster
C. Erlichman
A. D. King
M. K. M. Kam
S. F. Leung
K. C. Chan
A. T. C. Chan
Investigational New Drugs, 2015, 33 : 985 - 991
[37] Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
Ma, B. B. Y.
Goh, B. C.
Lim, W. T.
Hui, E. P.
Tan, E. H.
Lopes, G. de Lima
Lo, K. W.
Li, L.
Loong, H.
Foster, N. R.
Erlichman, C.
King, A. D.
Kam, M. K. M.
Leung, S. F.
Chan, K. C.
Chan, A. T. C.
INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 985 - 991
[38] A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
Ma, Cynthia X.
Suman, Vera
Goetz, Matthew P.
Northfelt, Donald
Burkard, Mark E.
Ademuyiwa, Foluso
Naughton, Michael
Margenthaler, Julie
Aft, Rebecca
Gray, Richard
Tevaarwerk, Amye
Wilke, Lee
Haddad, Tufia
Moynihan, Timothy
Loprinzi, Charles
Hieken, Tina
Barnell, Erica K.
Skidmore, Zachary L.
Feng, Yan-Yang
Krysiak, Kilannin
Hoog, Jeremy
Guo, Zhanfang
Nehring, Leslie
Wisinski, Kari B.
Mardis, Elaine
Hagemann, Ian S.
Vij, Kiran
Sanati, Souzan
Al-Kateb, Hussam
Griffith, Obi L.
Griffith, Malachi
Doyle, Laurence
Erlichman, Charles
Ellis, Matthew J.
CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6823 - 6832
[39] First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity
Yap, T. A.
Patnaik, A.
Fearen, I.
Olmos, D.
Papadopoulos, K.
Tunariu, N.
Sullivan, D.
Yan, L.
De Bono, J. S.
Tolcher, A. W.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[40] PHASE II TRIAL OF THE AKT INHIBITOR MK-2206 PLUS ERLOTINIB (ERL) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED AFTER PRIOR BENEFIT (RESPONSE OR STABLE DISEASE) FROM ERL: INTERIM RESULTS FROM PHII-108 (NCI 8698), A CALIFORNIA CANCER CONSORTIUM TRIAL
Lara, Primo
Longmate, Jeffrey
Mack, Philip C.
Kelly, Karen
Li, Tianhong
Koczywas, Mariana
Reckamp, Karen
Gandara, David
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S105 - S106

← 1 2 3 4 5 →